GILD Trading Analysis - 10/23/2026 03:14 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge and are separated from the data-driven analysis below:

• Gilead Sciences (GILD) recently announced positive Phase 3 data for a novel HIV treatment, reinforcing its franchise leadership.
• The company declared a quarterly dividend of $0.82 per share with an ex-dividend date of 2026-09-15, supporting income appeal.
• Analysts have noted steady institutional accumulation in large-cap biopharma amid sector rotation.
• No major earnings catalyst is scheduled before the next major options expiration of 2026-11-20 per general calendar knowledge.
• News context: Product pipeline strength and dividend stability may underpin the bullish options flow seen in embedded data, though embedded fundamentals show negative trailing EPS.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E is 17.70; trailing EPS is -2.60 (negative profitability).
• Dividend yield is 2.10% with dividend rate of 3.28 and ex-dividend date 2026-09-15.
• Market cap is 194,323,763,672.00 with shares outstanding of 1,239,955,000.00.
• Beta is 0.03 (very low market sensitivity); 52-week high 160.51, low 114.02.
• Institutional ownership is 67.61%; average volume 5,643,000.00.
• Historical volatility is 24.46%; fiscal year end 2025-12-01.
• PEG ratio, forward P/E, price/book, revenue, margins, ROE, debt/equity, FCF, analyst target, and recommendation key are null/not provided.

Fundamentals show low valuation multiple (P/E 17.70) but negative earnings (EPS -2.60) and missing margin/data. This diverges from the bullish technical and options sentiment which imply price strength absent fundamental confirmation.

Current Market Position

Current price from indicators is 156.73 (as of 2026-10-22 close). Minute bars show 2026-10-22 open 154.24, low 153.00, high 157.42, close 156.73 with volume 4,033,284. Last 2026-10-23 14:45 bar: open 156.69, high 156.72, low 156.69, close 156.72, volume 35,165. Intraday momentum is flat-to-slight-up after a 2026-10-22 rally from 153.00 to 157.15 area.

Technical Analysis

SMAs aligned bullish: price 156.73 > SMA5 155.31 > SMA20 150.71 > SMA50 148.46 (no bear cross). RSI 68.86 near overbought (>70 warning). MACD 2.48 > signal 1.98, hist 0.50 positive. Bollinger: price above middle, below upper 159.18 (room to upper). 30-day range: price near top (156.73 vs 160.51 high).

True Sentiment Analysis (Delta 40-60 Options)

Options flow sentiment: Bullish

Call Dollar Volume: 516,715.00 (64.0%) Put Dollar Volume: 290,305.00 (36.0%) Total: 807,020.00

Call contracts 507 vs put 313; call trades 37 vs put 13. Pure directional conviction (Delta 40-60) shows 64% call dollar share, confirming bullish near-term expectation. No divergence from technical uptrend; both align.

Key Price Levels (Observational Only)